Christina Ohnsman

Company: Tern Therapeutics

Job title: Chief Medical Officer

Seminars:

Spearheading Fast Progression of TTX-381 through the Value Chain to Tackle Rapid Onset of Rare Diseases 10:00 am

Discussing the necessity of accelerating Tern Therapeutics TTX-381 development to provide patients with CLN2 Disease an alternative therapy Highlighting the steps taken to maximize speed of development and efficacy of therapy to ensure regulatory approval and quick accessibility Evaluating the goals for TTX-381 for the next year to encourage rapid progression of therapies for other…Read more

day: Conference Day Two